MINNEAPOLIS--(BUSINESS WIRE)--Nov. 17, 2005--Medtronic, Inc. (NYSE:MDT) today announced that it has submitted its first pre-market approval (PMA) module to the U.S. Food and Drug Administration for the Talent(TM) Thoracic stent graft system. These stent grafts are used to treat thoracic aneurysms, which are dangerous bulges in the aorta - the body’s largest artery - that can rupture without warning.